Introduction

1,3,4-Thiadiazoles are one of the prevalent and significant structural moieties1,2,3 in pharmaceuticals and agrochemicals having broad spectra of bioactivities, including anti-inflammatory4,5, antihypertensive6, antibacterial7, antituberculosis8, anticonvulsant9, antimicrobial10, antidepressants11, antileishmanial12 and anticancer13,14.

It has been reported that the compounds containing furan showed broad-spectrum bioactivities. A wide range of derivatives such as dibenzoylureas15, diacylhydrazines16,17,18,19,20,21, acylhydrazones22,23,24,25, semicarbazide26, pyrazole, 1,2,4-triazole27, 1,3,4-oxadiazole28 and carbamic acid esters29,30 containing 5-phenyl-2-furan moiety has been synthesized and studied in our group for the development of novel chemical entities as a lead molecule in drug and agrochemical discovery. All the compounds showed diverse and significant bioactivities such as fungicidal, insecticidal and antitumor activities.

The standard method for the synthesis of 1,3,4-thiadiazoles involves cyclization of acylhydrazines (N,N-diacylhydrazines and monoacylhydrazines etc.) or thiohydrazines (thiosemicarbazides, bithioureas and thiocarbazides etc.) employing usually POCl331,32, PCl533, FeCl334 or H2SO435 as dehydrating agents. The other important way is via the transformation of the oxygen atom in 1,3,4-oxadiazole, which acts as the bioisostere of 1,3,4-thiadiazole, to sulfur using P2S536 and thiourea37. Thionation of acylhydrazines by the treatment of Lawesson’s reagent followed by cyclization and dehydrosulfurization was reported to produce 1,3,4-thiadiazoles in good yields38,39. Recently, there has been growing interests in the application of microwave irradiation in chemical reaction, the salient features being improved reaction rates and increased yields28,40,41.

In continuation of our research on the synthesis of biological heterocyclic compounds, a series of novel 1,3,4-thiadiazole derivatives containing 5-phenyl-2- furan moiety was synthesized by an efficient approach under microwave irradiation (Fig. 1). Their fungicidal activity was evaluated.

Figure 1
figure 1

Design strategy for the title compounds.

Results and Discussion

Synthesis

Synthesis of the title compounds 2,5-disubstituted-1,3,4-thiadiazoles (see supplementary information for 1H NMR and 13C NMR spectra) was achieved following a convenient procedure starting from commercially available 2-furoic acid and the substituted anilines as outlined in Fig. 2. 5-subsitituted phenyl-2-furoic acids 2 were prepared by the method of Meerwein arylation using copper (II)-catalyzed decomposition of diazonium salts. The diacylhydrazines 3 were obtained in moderate to good yields by the reaction of different 5-substituted phenyl-2-furoic chloride with differently substituted benzoylhydrazides in refluxing anhydrous dichloromethane.

Figure 2
figure 2

General synthetic procedure for title compounds.

Thionation of diacylhydrazines 3 with Lawesson’s reagent followed by oxidative cyclization in dry toluene led to the title compounds 1,3,4-thiadiazoles in good yields. Several selected one-pot microwave-assisted syntheses were carried out to establish the general validity check of the newly developed method. This method appeared to be economical and expeditious. The reaction proceeded well and smoothly under microwave irradiation within 15 min whereas 5–7 h was required under conventional reflux condition (Table 1). The yields were raised from 8.3% to 18.3% compared to the conventional method. This presented method, which was more facilitated and rapid than conventional method, indicated a good contribution to microwave-assisted synthetic methodologies.

Table 1 Comparison Between Conventional Heating Method and Microwave Assisted Method for Synthesis of Title Compounds in Terms of Time and Yield.

The reaction of diacylhydrazines 3 with Lawesson’s reagent was also screened in different solvents including tetrahydrofuran, dioxane and xylene, but afforded less yields when compared to toluene.

Fungicidal activity

In vitro fungicidal activities of title compounds against P. infestans, V. mali, P. aspamgi, C. fulvum Cke., A. tenuis Nees were listed in Table 2. The bioassay results showed that the title compounds had significant activities against the selected fungi. The comparison of the fungicidal activity of title compounds for five test fungi to those of positive control fungicides reached the following conclusions: (a) Compounds I10, I18, I19, I25 and I31 exhibited excellent activity against P. infestans and the EC50 values were 7.4, 5.7, 4.1, 8.4 and 18.1 μg/mL respectively, which were better than that of the commercial fungicides pyrimorph (EC50 = 25.2 μg mL−1) and hymexazol (EC50 = 29.1 μg mL−1). The preliminary structure-activity relationship showed that phenyl group without any substituent (R1 = H, such as compounds I10, I18 and I25 or R2 = H, compound I19) was favored to the bioactivity. (b) For V. mali, compounds I18 and I21 showed considerable activity. Compound I18 exhibited higher activity (EC50 = 9.7 μg mL−1) than that of control fungicides pyrimorph (EC50 = 32.5 μg mL−1) and hymexazol (EC50 = 10.9 μg mL−1). Compound I21 had better activity (EC50 = 20.4 μg mL−1) than that of pyrimorph, but lower than that of hymexazol. (c) Compounds I18 and I20 had favorable fungicidal activity against P. aspamgi (EC50 = 21.7 and 23.1 μg mL−1) and C. fulvum (EC50 = 21.4 and 22.8 μg mL−1), which were better than that of pyrimorph, but lower than hymexazol. Besides that, compounds I12 and I29, I2 and I5 showed significant activities against P. aspamgi and C. fulvum respectively. (d) All the compounds showed lower effect against A. tenuis except compound I18, which gave excellent activity and the EC50 value (5.8 μg mL−1) was better than that of pyrimorph (17.3 μg mL−1) and hymexazol (7.4 μg mL−1).

Table 2 In Vitro Fungicidal Activities of Title Compounds against Five Fungus Species.

Due to the favorable in vitro bioactivity, in vivo activity against four fungi was also assessed and the results were presented in Table 3. Tendency of the results was in consistent with that of the in vitro bioactivity. Compounds I10, I18, I19 and I25 exhibited a significant inhibition effect (exceeding 80% efficacy rate) against P. infestans and the antifungal activities (control efficacy of 83.85 ± 1.85%, 84.21 ± 1.58, 87.15 ± 2.02 and 80.18 ± 2.01%) were better than that of both pyrimorph (77.15 ± 1.84%) and hymexazol (64.27 ± 1.72%) at 500 μg mL−1. For C. fulvum, it was worthy to note that compounds I18 and I20, which efficacy rates were 77.14 ± 2.02% and 71.55 ± 1.20%, were found to be much more effective compared to the fungicide pyrimorph (46.21 ± 1.19%). Meanwhile, all the tested compounds were found safe for the plants.

Table 3 In Vivo Fungicidal Activities of Title Compounds against Four Fungus Species at 500 μg mL−1.

Compared to the precursor diacylhydrazines 3 and cyclodehydrated compounds 1,3,4-oxadiazoles (Fig. 1), the title compounds exhibited improved and higher fungicidal activity to a certain extent. The fungicidal spectra were also broadened.

From the in vitro and in vivo bioassay results, it indicated that title compounds possessed significant fungicidal activities, especially against the P. infestans. Among them, compound I18 gave great promise as a lead compound for further development. The fungicidal spectra against twenty fungi species of compound I18 were evaluated and the results were listed in Table 4. The results revealed that compound I18 had broad and excellent fungicidal activities, except against T. roseum, B. cinerea and P. melonis.

Table 4 In Vitro Fungicidal Activities of Compound I18 Against Twenty Fungus Species at 50 μg mL−1.

Effects of compound I18 on morphological and ultrastructural variation of P. infestans

Compound I18 was effective in inhibiting mycelia radial growth on PDA medium (Table 2). Along the surface of culture media without compound I18, mycelium of P. capsici grew smoothly and uniformly. The whole colony appeared to be radiative from its centre and the rim of the colony was regular. However, in the media with compound I18, the growth of mycelium was seriously inhibited. The rim of the colony was changed to be irregular and concave-convex and was not as smooth as that of blank control. Furthermore, high concentration of compound I18 made this abnormal appearance much clear.

Scanning electron micrographs (SEM) images of P. infestans treated with compound I18 demonstrated the effects on the morphology of the hyphae (Fig. 3). SEM images revealed that the mycelium grew freshly and normally (the diameter was about 2.03 μm) in the culture media of blank control with low density and fine structure (Fig. 3A,C). However, in culture media with compound I18 of 50 μg mL−1, mycelium grew abnormally with relatively high density of colony and some mycelia were entangled with each other. Some parts of the mycelium swelled (the diameter was about 4.14 μm) and distorted to form the “beaded” morphology on the tip and others ruptured to produce shriveled and empty mycelia (Fig. 3B,E).

Figure 3
figure 3

Scanning electron micrographs (SEM) of the hyphae from the colony of P. infestans:

(A,B,E) 700×, bars, 50.0 μm; (C,D) 4000×, bars, 10.0 μm. (A,C) Sections of P. infestans hyphae were grown on PDA (blank control). (B,D,E) Sections of P. infestans hyphae were grown on PDA with 50 μg mL−1 compound I18.

P. infestans mycelial tip (5 mm) from the rim of an actively growing colony on PDA medium was investigated by TEM (Fig. 4). The blank control mycelia of P. infestans grown in the absence of compound I18 demonstrated some cytological and ultrastructural features, which were typical vegetative hyphae of the genus42,43 (Fig. 4A,D). There were normal cell wall deposition and undulated plasmalemma and cytoplasm containing vacuole and mitochondria were observed.

Figure 4
figure 4

Transmission electron micrographs (TEM) of P. infestans hyphae in transversal

(A,C) and longitudinal (B,D–G). (A,B) Sections of P. infestans hyphae were grown on PDA (blank control). (C–G) Sections of P. infestans hyphae were grown on PDA medium with 50 μg mL−1 compound I18.

In the presence of compound I18 at 50 μg mL−1, extensive cell wall thickening was the most conspicuous ultrastructural variation observed in hyphae (Fig. 4C,D). The number of vacuoles increased and vacuoles were distorted and disrupted under treatment with compound I18 (3D). Vacuoles play an important role in mycelial growth, meanwhile with the function of maintaining fungal turgor pressure. The phenomena caused by compound I18 were roughly the same as those caused by pyrimorph and dimethomorph, which had an effect on the biosynthesis of cell walls43,44,45. Hence, compound I18 may retard fungal growth by acting on cell wall synthesis. The “beaded” hyphae were separated by the cell walls and false septa (Fig. 4C,H), which blocked the nutrition transportation and led to cells senescence and death. It revealed that the multilayer cell walls were formed and there was cytoplasmic substance in the interlayer of the proliferative cell walls (Fig. 4D–F). Gradually the cell walls exfoliated obviously and the cytoplasmic substance osmosis in the interlayer increased. Finally the cell wall ruptured and the cytoplasmic substance outflowed (Fig. 4F). That was the reason of producing shriveled and empty mycelia observed in SEM (Fig. 3B,E). Mitochondria and cell nuclear had the same appearance as blank control hyphae.

Conclusions

In summary, we synthesized a series of 2-substituted phenyl-5-(5′-substituted phenyl-2′-furoyl)-1,3,4-thiadiazoles using Lawesson’s reagent by an efficient approach under microwave irradiation in good yields. The title compounds displayed significant fungicidal activity against various fungi, especially exhibited excellent fungicidal activity against P. infestans. Moreover, it was speculated that compound I18 might act on the synthesis of cell walls from morphological and ultrastructural studies by SEM and TEM, which also revealed that compound I18 could block the nutrition transportation and led to cells senescence and death. These results suggested that title compounds were eligible to be development candidates and compound I18 as a promising lead compound was worthy to be further discovery, especially against P. infestans. However, further research should also be undergoing to confirm the specific mode of action of the title compounds.

Materials and Methods

Instruments

All the melting points were determined with a Cole-Parmer melting point apparatus (Cole-Parmer, Vernon Hills, Illinois, USA) while the thermometer was uncorrected. IR spectra were recorded on a Nicolet NEXUS-470 FTIR spectrometer (International Equipment Trading Ltd., Vernon Hills, Illinois, USA) with KBr pellets. 1H NMR and 13C NMR spectra were recorded with Bruker DPX400 (Bruker, Fallanden, Switzerland), while tetramethylsilane was used as an internal standard. Analytical thin-layer chromatography was carried out on silica gel 60 F254 plates and spots were visualized with ultraviolet light. Mass spectra were measured on a Bruker APEX IV spectrometer (Bruker, Fallanden, Switzerland). Elemental analyses were performed on a Vario EL elemental analyzer. The microwave-assisted reaction was carried out with a CEM Microwave synthesizer (CEM Discover S-Class).

Synthetic procedures

General synthetic procedure for the key intermediates

Intermediates 5-substituted phenyl-2-furoic acids 2 were synthesized from substituted aniline by Meerwein arylation reaction according to the reported literatures25,26,27,28,29. Intermediates diacylhydrazides 3 were synthesized using our previous procedure17,28.

General procedure for the synthesis of title compounds

A mixture of diacylhydrazines 3 (1 mmol) and Lawesson’s reagent (1.5 mmol) in toluene (10 mL) was refluxed for 5–7 h. After completion of the reaction as monitored by TLC, the reaction was quenched by addition of the saturated NaHCO3 solution. The organic layer was washed with brine, dried over MgSO4 and concentrated in vacuo. The residue was recrystalized from ethanol to afford pure products I.

General procedure for the synthesis of title compounds by microwave radiation

All reactions were carried out in a pressure tube, sealed with a Teflon septum. The mixture of the diacylhydraziness 3 (1 mmol) and Lawesson’s reagent (1.5 mmol) in toluene (20 mL) was taken in the pressure tube. The pressure tube was introduced to the centre of a CEM Discover microwave oven and irradiated for 15 min at 150 W (reaction temperature was set to 110 °C). After completion of the reaction, the reaction mixture was allowed to cool and then, it was poured slowly with stirring into the saturated NaHCO3 solution. The organic layer was washed with brine, dried over MgSO4 and concentrated in vacuo. The residue was recrystalized from ethanol to afford pure products I.

2-(4-Methoxyphenyl)-5-(5-(4-nitrophenyl)furan-2-yl)-1,3,4-thiadiazole (I1)

Yellow solid, m.p. 238–239 °C; IR (KBr) νmax: 1603.52, 1513.85, 1434.78, 1411.64, 1335.46, 1257.36, 1172.51, 1106.94, 1030.77 cm−1. 1H NMR (400 MHz, CDCl3) 3.90 (s, 3H, OCH3), 7.02 (d, J = 8.8 Hz, 2H, PhH-Thia), 7.06 (d, J = 4.0 Hz, 1H, FuH), 7.33 (d, J = 3.6 Hz, 1H, FuH), 7.91 (d, J = 9.2 Hz, 2H, PhH-Fu), 7.97 (d, J = 8.4 Hz, 2H, PhH-Thia), 8.31 (d, J = 8.8 Hz, 2H, PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 167.49 (C-2, Thia), 162.05 (C-4′, Ph-Thia), 156.59 (C-5, Thia), 153.44 (C-5, Fu), 146.99(C-4, Ph-Fu), 146.85 (C-2, Fu), 135.01 (C-1, Ph-Fu), 129.47 (2C, C-2′, C-6′, Ph-Thia), 124.45 (2C, C-2, C-6, Ph-Fu), 124.36 (2C, C-3, C-5, Ph-Fu), 122.27 (C-1′, Ph-Thia), 114.56 (2C, C-3′, C-5′, Ph-Thia), 113.52 (C-3, Fu), 111.19 (C-4, Fu), 55.42 (OCH3). ESIMS (m/z): 380.1 [M + H]+. Anal. Calcd. (%) for C19H13N3O4S: C, 60.15; H, 3.45; N, 11.08. Found: C, 59.98; H, 3.55; N, 11.17.

2-(4-Bromophenyl)-5-(5-(2-chlorophenyl)furan-2-yl)-1,3,4-thiadiazole (I2)

Yellow solid, m.p. 196–197 °C; IR (KBr) νmax: 3063.37, 1586.16, 1530.24, 1469.49, 1441.53, 1066.44, 1020.16 cm−1. 1H NMR (400 MHz, CDCl3) 7.26–7.32 (m, 2H, FuH + PhH-Fu), 7.35–7.38 (m, 2H, FuH + PhH-Fu), 7.49 (d, J = 8.0 Hz, 1H, PhH-Fu), 7.64 (d, J = 8.8 Hz, 2H, PhH-Thia), 7.88 (d, J = 8.4 Hz, 2H, PhH-Thia), 7.94 (dd, J = 1.4, 8.0 Hz, 1H, PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 166.21 (C-2, Thia), 158.29 (C-5, Thia), 152.91 (C-5, Fu), 144.78 (C-2, Fu), 132.57 (2C, C-3′, C-5′, Ph-Thia), 131.09 (C-4, Ph-Fu), 130.89 (C-1, Ph-Fu), 129.37 (C-3, Ph-Fu), 129.31 (2C, C-2′, C-6′, Ph-Thia), 128.93 (C-1′, Ph-Thia), 128.37 (C-6, Ph-Fu), 128.07 (C-2, Ph-Fu), 127.19 (C-5, Ph-Fu), 125.73 (C-4′, Ph-Thia), 113.87 (C-3, Fu), 113.57 (C-4, Fu). ESIMS (m/z): 441.1 [M + Na]+. Anal. Calcd. (%) for C18H10BrClN2OS: C, 51.76; H, 2.41; N, 6.71. Found: C, 51.48; H, 2.63; N, 6.66.

2-(4-Methoxyphenyl)-5-(5-(4-chlorophenyl)furan-2-yl)-1,3,4-thiadiazole (I3)

Yellow solid, m.p. 169–170 °C; IR (KBr) νmax: 3092.30, 1606.41, 1518.67, 1480.10, 1264.11, 1171.54, 1091.51, 1019.19 cm−1. 1H NMR (400 MHz, CDCl3) 3.89 (s, 3H, OCH3), 6.82 (d, J = 3.6 Hz, 1H, FuH), 7.01 (d, J = 8.8 Hz, 2H, PhH-Thia), 7.27 (d, J = 3.6 Hz, 1H, FuH), 7.41 (d, J = 8.4 Hz, 2H, PhH-Fu), 7.69 (d, J = 8.8 Hz, 2H, PhH-Thia), 7.95 (d, J = 8.4 Hz, 2H, PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 167.03 (C-2, Thia), 161.96 (C-4′, Ph-Thia), 157.18 (C-5, Thia), 155.11 (C-5, Fu), 145.32 (C-2, Fu), 134.33 (C-4, Ph-Fu), 129.51 (2C, C-2′, C-6′, Ph-Thia), 129.18 (2C, C-3, C-5, Ph-Fu), 128.11 (C-1, Ph-Fu), 125.54 (2C, C-2, C-6, Ph-Fu), 122.60 (C-1′, Ph-Thia), 114.64 (2C, C-3′, C-5′, Ph-Thia), 113.55 (C-3, Fu), 108.18 (C-4, Fu), 55.54 (OCH3). ESIMS (m/z): 369.1 [M + H]+. Anal. Calcd. (%) for C19H13ClN2O2S: C, 61.87; H, 3.55; N, 7.60. Found: C, 62.09; H, 3.23; N, 7.89.

2-(5-(4-Chlorophenyl)furan-2-yl)-5-(2-methoxyphenyl)-1,3,4-thiadiazole (I4)

Yellow solid, m.p. 160–161 °C; IR (KBr) νmax: 3411.46, 1599.66, 1536.02, 1478.17, 1432.85, 1298.82, 1249.65, 1164.79, 1093.44, 1050.05, 1020.16 cm−1. 1H NMR (400 MHz, CDCl3) 4.07 (s, 3H, OCH3), 6.82 (d, J = 3.6 Hz, 1H, FuH), 7.07 (dd, J = 3.2, 8.4 Hz, 1H, PhH-Thia), 7.14 (t, J = 7.6 Hz, 1H, PhH-Thia), 7.28 (d, J = 3.6 Hz, 1H, FuH), 7.40–7.42 (m, 2H, PhH-Fu), 7.47–7.51 (m, 1H, PhH-Thia), 7.70–7.73 (m, 2H, PhH-Fu), 8.55 (dd, J = 1.6, 8.0 Hz, 1H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 160.88 (C-2, Thia), 158.98 (C-5, Thia), 155.79 (C-2′, Ph-Thia), 154.85 (C-5, Fu), 145.90 (C-2, Fu), 134.10 (C-4, Ph-Fu), 132.11 (C-4′, Ph-Thia), 129.08 (2C, C-3, C-5, Ph-Fu), 128.74 (C-6′, Ph-Thia), 128.25 (C-1, Ph-Fu), 125.50 (2C, C-2, C-6, Ph-Fu), 121.35 (C-5′, Ph-Thia), 119.02 (C-1′, Ph-Thia), 113.12 (C-3, Fu), 111.30 (C-3′, Ph-Thia), 108.08 (C-4, Fu), 55.80 (OCH3). ESIMS (m/z): 369.2 [M + H]+. Anal. Calcd. (%) for C19H13ClN2O2S: C, 61.87; H, 3.55; N, 7.60. Found: C, 61.62; H, 3.74; N, 7.43.

2-(3-Chlorophenyl)-5-(5-(4-chlorophenyl)furan-2-yl)-1,3,4-thiadiazole (I5)

Yellow solid, m.p. 178–179 °C; IR (KBr) νmax: 3048.91, 1684.52, 1573.63, 1536.99, 1479.13, 1432.85, 1093.44 cm−1. 1H NMR (400 MHz, CDCl3) 6.84 (d, J = 3.6 Hz, 1H, FuH), 7.33 (d, J = 3.6 Hz, 1H, FuH), 7.41–7.50 (m, 4H, 2PhH-Thia + 2PhH-Fu), 7.70 (d, J = 8.0 Hz, 2H, PhH-Fu), 7.89 (d, J = 7.2 Hz, 1H, PhH-Thia), 8.03 (s, 1H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 165.59 (C-2, Thia), 158.36 (C-5, Thia), 155.55 (C-5, Fu), 144.98 (C-2, Fu), 135.29 (C-1′, Ph-Thia), 134.54 (C-4, Ph-Fu), 131.52 (C-3′, Ph-Thia), 131.10 (C-5′, Ph-Thia), 130.50 (C-6′, Ph-Thia), 129.20 (2C, C-3, C-5, Ph-Fu), 127.93 (C-1, Ph-Fu), 127.76 (C-4′, Ph-Thia), 125.99 (C-2′, Ph-Thia), 125.59 (2C, C-2, C-6, Ph-Fu), 114.16 (C-3, Fu), 108.24 (C-4, Fu). ESIMS (m/z): 395.1 [M + Na]+. Anal. Calcd. (%) for C18H10Cl2N2OS: C, 57.92; H, 2.70; N, 7.51. Found: C, 58.14; H, 2.81; N, 7.29.

2-(5-(4-Bromophenyl)furan-2-yl)-5-(4-methoxyphenyl)-1,3,4-thiadiazole (I6)

Yellow solid, m.p. 201–202 °C; IR (KBr) νmax: 3068.41, 1621.32, 1543.52, 1497.42, 1454.21, 1272.43, 1175.25, 1102.24, 1053.21 cm−1. 1H NMR (400 MHz, CDCl3) 3.89 (s, 3H, OCH3), 6.83 (d, J = 3.6 Hz, 1H, FuH), 7.01 (d, J = 8.8 Hz, 2H, PhH-Thia), 7.26 (d, J = 3.6 Hz, 1H, FuH), 7.56 (d, J = 8.8 Hz, 2H, PhH-Fu), 7.63 (d, J = 8.8 Hz, 2H, PhH-Fu), 7.95 (d, J = 9.2 Hz, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 166.98 (C-2, Thia), 161.95 (C-4′, Ph-Thia), 157.16 (C-5, Thia), 155.06 (C-5, Fu), 145.28 (C-2, Fu), 132.03 (2C, C-3, C-5, Ph-Fu), 129.44 (2C, C-2′, C-6′, Ph-Thia), 128.44 (C-1, Ph-Fu), 125.69 (2C, C-2, C-6, Ph-Fu), 122.51 (C-1′, Ph-Thia), 122.44 (C-4, Ph-Fu), 114.56 (2C, C-3′, C-5′, Ph-Thia), 113.49 (C-3, Fu), 108.20 (C-4, Fu), 55.46 (OCH3). ESIMS (m/z): 437.1[M + Na]+. Anal. Calcd. (%) for C19H13BrN2O2S: C, 55.22; H, 3.17; N, 6.78. Found: C, 55.01; H, 3.42; N, 6.59.

2-(4-Chlorophenyl)-5-(5-(2-chlorophenyl)furan-2-yl)-1,3,4-thiadiazole (I7)

Light yellow solid, m.p. 195–196 °C; IR (KBr) νmax: 3031.71, 1693.12, 1565.92, 1547.87, 1481.21, 1475.85, 1089.49, 1021.67 cm−1. 1H NMR (400 MHz, CDCl3) 7.27–7.31 (m, 1H, PhH-Fu), 7.32 (d, J = 3.6 Hz, 1H, FuH), 7.36 (d, J = 3.6 Hz, 1H, FuH), 7.37–7.41 (m, 1H, PhH-Fu), 7.47–7.50 (m, 3H, 2PhH-Thia + PhH-Fu), 7.94–7.98 (m, 3H, 2PhH-Thia + PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 166.03 (C-2, Thia), 158.18 (C-5, Thia), 152.79 (C-5, Fu), 144.68 (C-2, Fu), 137.28 (C-4′, Ph-Thia), 130.98 (C-4, Ph-Fu), 130.79 (C-1, Ph-Fu), 129.51 (2C, C-3′, C-5′, Ph-Thia), 129.26 (C-3, Ph-Fu), 129.04 (2C, C-2′, C-6′, Ph-Thia), 128.39 (C-1′, Ph-Thia), 128.27 (C-6, Ph-Fu), 127.97 (C-2, Ph-Fu), 127.08 (C-5, Ph-Fu), 113.74 (C-3, Fu), 113.46 (C-4, Fu). ESIMS (m/z): 373.1 [M + H]+. Anal. Calcd. (%) for C18H10Cl2N2OS: C, 57.92; H, 2.70; N, 7.51. Found: C, 58.25; H, 2.49; N, 7.76.

2-(2-Chlorophenyl)-5-(5-(2-chlorophenyl)furan-2-yl)-1,3,4-thiadiazole (I8)

Light yellow solid, m.p. 145–146 °C; IR (KBr) νmax: 3079.52, 1651.43, 1574.96, 1514.64, 1492.31, 1445.76, 1046.49, 1015.34 cm−1. 1H NMR (400 MHz, CDCl3) 7.27–7.31 (m, 1H, PhH-Fu), 7.33–7.48 (m, 6H, 2FuH + 2PhH-Thia + 2PhH-Fu), 7.55–7.57 (m, 1H, PhH-Fu), 7.98–8.00 (m, 1H, PhH-Thia), 8.40–8.43 (m, 1H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 162.53 (C-2, Thia), 159.54 (C-5, Thia), 152.74 (C-5, Fu), 144.76 (C-2, Fu), 132.47 (C-1′, Ph-Thia), 131.65 (C-4′, Ph-Thia), 131.17 (C-3′, Ph-Thia), 130.94 (C-4, Ph-Fu), 130.74 (C-1, Ph-Fu), 130.61 (C-6′, Ph-Thia), 129.19 (C-3, Ph-Fu), 128.78 (C-2′, Ph-Thia), 128.33 (C-6, Ph-Fu), 128.02 (C-2, Ph-Fu), 127.43 (C-5′, Ph-Thia), 127.10 (C-5, Ph-Fu), 113.75 (C-3, Fu), 113.47 (C-4, Fu). ESIMS (m/z): 373.2 [M + H]+. Anal. Calcd. (%) for C18H10Cl2N2OS: C, 57.92; H, 2.70; N, 7.51. Found: C, 57.76; H, 2.81; N, 7.83.

2-(5-(2-Chlorophenyl)furan-2-yl)-5-(4-ethoxyphenyl)-1,3,4-thiadiazole (I9)

Yellow solid, m.p. 163–164 °C; IR (KBr) νmax: 3103.43, 1646.32, 1575.36, 1492.60, 1278.82, 1229.43, 1182.47, 1071.43, 1021.34 cm−1. 1H NMR (400 MHz, CDCl3) 1.45 (t, J = 6.8 Hz, 3H, C-CH3), 4.11 (q, J = 6.8 Hz, 2H, O-CH2-C), 6.98 (d, J = 8.0 Hz, 2H, PhH-Thia), 7.25–7.31 (m, 3H, 2FuH + PhH-Fu), 7.36–7.39 (m, 1H, PhH-Fu), 7.47 (d, J = 8.4 Hz, 1H, PhH-Fu), 7.92–7.96 (m, 3H, 2PhH-Thia + PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 167.20 (C-2, Thia), 161.39 (C-4′, Ph-Thia), 157.17 (C-5, Thia), 152.36 (C-5, Fu), 144.97 (C-2, Fu), 130.93 (C-4, Ph-Fu), 130.66 (C-1, Ph-Fu), 129.47 (2C, C-2′, C-6′, Ph-Thia), 129.08 (C-3, Ph-Fu), 128.22 (C-6, Ph-Fu), 128.06 (C-2, Ph-Fu), 127.06 (C-5, Ph-Fu), 122.35 (C-1′, Ph-Thia), 115.03 (2C, C-3′, C-5′, Ph-Thia), 113.39 (C-3, Fu), 113.18 (C-4, Fu), 63.75 (OCH2), 14.71 (CH3). ESIMS (m/z): 383.1 [M + H]+. Anal. Calcd. (%) for C20H15ClN2O2S: C, 62.74; H, 3.95; N, 7.32. Found: C, 62.99; H, 4.09; N, 7.61.

2-(5-(2-Chlorophenyl)furan-2-yl)-5-phenyl-1,3,4-thiadiazole (I10)

Light yellow solid, m.p. 139–140 °C; IR (KBr) νmax: 3093.82, 1646.32, 1607.62, 1575.36, 1492.60, 1427.32, 1264.92, 1229.43, 1182.47, 1071.43, 1017.51 cm−1. 1H NMR (400 MHz, CDCl3) 7.28–7.30 (m, 1H, PhH-Fu), 7.31 (d, J = 3.6 Hz, 1H, FuH), 7.34 (d, J = 3.6 Hz, 1H, FuH), 7.36–7.40 (m, 1H, PhH-Fu), 7.47–7.51 (m, 4H, 2PhH-Thia + 2PhH-Fu), 7.95 (dd, J = 1.2, 8.0 Hz, 1H, PhH-Thia), 8.00–8.03 (m, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 167.31 (C-2, Thia), 157.99 (C-5, Thia), 152.62 (C-5, Fu), 144.88 (C-2, Fu), 131.18 (C-1′, Ph-Thia), 130.96 (C-4, Ph-Fu), 130.75 (C-1, Ph-Fu), 129.92 (C-4′, Ph-Thia), 129.22 (2C, C-2′, C-6′, Ph-Thia), 129.18 (C-3, Ph-Fu), 128.28 (C-6, Ph-Fu), 128.05 (C-2, Ph-Fu), 127.93 (2C, C-3′, C-5′, Ph-Thia), 127.08 (C-5, Ph-Fu), 113.50 (C-3, Fu), 113.43 (C-4, Fu). ESIMS (m/z): 339.1 [M + H]+. Anal. Calcd. (%) for C18H11ClN2OS: C, 63.81; H, 3.27; N, 8.27. Found: C, 63.65; H, 3.56; N, 8.02.

2-(4-Chlorophenyl)-5-(5-(2,4-difluorophenyl)furan-2-yl)-1,3,4-thiadiazole (I11)

Yellow solid, m.p. 192–193 °C; IR (KBr) νmax: 1679.24, 1609.67, 1584.53, 1499.87, 1453.83, 1434.42, 1421.73, 1225.62, 1158.15, 1095.83, 1016.74 cm−1. 1H NMR (400 MHz, CDCl3) 6.92–7.03 (m, 3H, FuH + 2PhH-Fu), 7.33 (d, J = 3.6 Hz, 1H, FuH), 7.48 (d, J = 8.4 Hz, 2H, PhH-Thia), 7.88–7.96 (m, 3H, 2PhH-Thia + PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 165.99 (C-2, Thia), 162.62 (dd, 1JC-F = 247.2 Hz, 3JC-F = 8.7 Hz, C-4, Ph-Fu), 159.23 (dd, 1JC-F = 253.1 Hz, 3JC-F = 11.4 Hz, C-2, Ph-Fu), 158.05 (C-5, Thia), 149.97 (C-5, Fu), 144.51 (C-2, Fu), 137.33 (C-4′, Ph-Thia), 129.53 (2C, C-3′, C-5′, Ph-Thia), 129.04 (2C, C-2′, C-6′, Ph-Thia), 128.33 (C-1′, Ph-Thia), 127.38 (dd, 3JC-F = 9.6 Hz, 3JC-F = 4.4 Hz, C-6, Ph-Fu), 114.54 (dd, 2JC-F = 12.0 Hz, 4JC-F = 3.9 Hz, C-1, Ph-Fu), 114.26 (C-3, Fu), 112.04 (d, 4JC-F = 3.6 Hz, C-4, Fu), 112.01 (dd, 2JC-F = 21.4 Hz, 4JC-F = 3.6 Hz, C-5, Ph-Fu), 104.77 (dd, 2JC-F = 25.4 Hz, 2JC-F = 25.4 Hz, C-3, Ph-Fu). ESIMS (m/z): 397.1 [M + Na]+. Anal. Calcd. (%) for C18H9ClF2N2OS: C, 57.68; H, 2.42; N, 7.47. Found: C, 57.33; H, 2.70; N, 7.19.

2-(2-Chlorophenyl)-5-(5-(2,4-difluorophenyl)furan-2-yl)-1,3,4-thiadiazole (I12)

Light yellow solid, m.p. 124–125 °C; IR (KBr) νmax: 1668.74, 1606.46, 1534.46, 1434.42, 1403.62, 1401.41, 1231.69, 1072.63, 1089.49 cm−1. 1H NMR (400 MHz, CDCl3) 6.92–7.04 (m, 3H, FuH + 2PhH-Fu), 7.37 (d, J = 3.6 Hz, 1H, FuH), 7.44–7.47 (m, 2H, PhH-Thia), 7.55–7.58 (m, 1H, PhH-Thia), 7.93–7.99 (m, 1H, PhH-Fu), 8.41–8.43 (m, 1H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 162.55 (dd, 1JC-F = 250.8 Hz, 3JC-F = 12.4 Hz, C-4, Ph-Fu), 162.42 (C-2, Thia), 159.37 (C-5, Thia), 159.19 (dd, 1JC-F = 252.2 Hz, 3JC-F = 10.6 Hz, C-2, Ph-Fu), 149.87 (C-5, Fu), 144.66 (C-2, Fu), 132.44 (C-1′, Ph-Thia), 131.65 (C-4′, Ph-Thia), 131.14 (C-3′, Ph-Thia), 130.61 (C-6′, Ph-Thia), 128.76 (C-2′, Ph-Thia), 127.44 (dd, 3JC-F = 9.5 Hz, 3JC-F = 4.3 Hz, C-6, Ph-Fu), 127.43 (C-5′, Ph-Thia), 114.58 (dd, 2JC-F = 12.0 Hz, 4JC-F = 3.9 Hz, C-1, Ph-Fu), 114.13 (C-3, Fu), 112.05 (d, 4JC-F = 3.6 Hz, C-4, Fu), 112.02 (dd, 2JC-F = 21.4 Hz, 4JC-F = 3.6 Hz, C-5, Ph-Fu), 104.71 (dd, 2JC-F = 25.4 Hz, 2JC-F = 25.4 Hz, C-3, Ph-Fu). ESIMS (m/z): 375.1 [M + H]+. Anal. Calcd. (%) for C18H9ClF2N2OS: C, 57.68; H, 2.42; N, 7.47. Found: C, 57.96; H, 2.67; N, 7.21.

2-(5-(2,4-Difluorophenyl)furan-2-yl)-5-(p-tolyl)-1,3,4-thiadiazole (I13)

Yellow solid, m.p. 172–173 °C; IR (KBr) νmax: 3121.15, 2912.65, 1630.87, 1555.83, 1478.71, 1457.92, 1415.57, 1279.53, 1118.69, 1080.87, 1037.93, 1010.14 cm−1. 1H NMR (400 MHz, CDCl3) 2.43 (s, 3H, CH3), 6.91–7.03 (m, 3H, FuH + 2PhH-Fu), 7.30–7.32 (m, 3H, FuH + 2PhH-Thia), 7.89–7.95 (m, 3H, 2PhH-Thia + PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 167.41 (C-2, Thia), 162.58 (dd, 1JC-F = 250.6 Hz, 3JC-F = 12.2 Hz, C-4, Ph-Fu), 159.24 (dd, 1JC-F = 255.7 Hz, 3JC-F = 14.3 Hz, C-2, Ph-Fu), 157.48 (C-5, Thia), 149.63 (C-5, Fu), 144.79 (C-2, Fu), 141.74 (C-4′′, Ph-Thia), 129.90 (2C, C-3′, C-5′, Ph-Thia), 127.83 (2C, C-2′, C-6′, Ph-Thia), 127.38 (dd, 3JC-F = 9.5 Hz, 3JC-F = 4.3 Hz, C-6, Ph-Fu), 127.13 (C-1′, Ph-Thia), 114.64 (dd, 2JC-F = 12.0 Hz, 4JC-F = 3.9 Hz, C-1, Ph-Fu), 113.81 (C-3, Fu), 112.02 (d, 4JC-F = 3.6 Hz, C-4, Fu), 112.00 (dd, 2JC-F = 21.3 Hz, 4JC-F = 3.6 Hz, C-5, Ph-Fu), 104.71 (dd, 2JC-F = 25.4 Hz, 2JC-F = 25.4 Hz, C-3, Ph-Fu), 21.53 (CH3). ESIMS (m/z): 355.2 [M + H]+. Anal. Calcd. (%) for C19H12F2N2OS: C, 64.40; H, 3.41; N, 7.91. Found: C, 64.14; H, 3.36; N, 7.79.

2-(5-(2,4-Difluorophenyl)furan-2-yl)-5-(4-methoxyphenyl)-1,3,4-thiadiazole (I14)

Yellow solid, m.p. 200–201 °C; IR (KBr) νmax: 1668.17, 1578.45, 1498.31, 1457.92, 1272.43, 1186.32, 1162.21, 1072.27 cm−1. 1H NMR (400 MHz, CDCl3) 3.89 (s, 3H, OCH3), 6.91–6.97 (m, 2H, FuH + PhH-Fu), 6.98–7.02 (m, 3H, 2PhH-Thia + PhH-Fu), 7.29 (d, J = 3.6 Hz, 1H, FuH), 7.89–7.96 (m, 3H, 2PhH-Thia + PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 167.05 (C-2, Thia), 162.55 (dd, 1JC-F = 250.4 Hz, 3JC-F = 12.2 Hz, C-4, Ph-Fu), 161.98 (C-4′, Ph-Thia), 159.21 (dd, 1JC-F = 254.1 Hz, 3JC-F = 12.5 Hz, C-2, Ph-Fu), 157.07 (C-5, Thia), 149.55 (C-5, Fu), 144.83 (C-2, Fu), 129.46 (2C, C-2′, C-6′, Ph-Thia), 127.35 (dd, 3JC-F = 9.5 Hz, 3JC-F = 4.3 Hz, C-6, Ph-Fu), 122.53 (C-1′, Ph-Thia), 114.67 (dd, 2JC-F = 12.0 Hz, 4JC-F = 3.9 Hz, C-1, Ph-Fu), 114.58 (2C, C-3′, C-5′, Ph-Thia), 113.63 (C-3, Fu), 112.03 (d, 4JC-F = 3.6 Hz, C-4, Fu), 112.01 (dd, 2JC-F = 21.4 Hz, 4JC-F = 3.6 Hz, C-5, Ph-Fu), 104.69 (dd, 2JC-F = 25.4 Hz, 2JC-F = 25.4 Hz, C-3, Ph-Fu), 55.47 (OCH3). ESIMS (m/z): 371.3 [M + H]+. Anal. Calcd. (%) for C19H12F2N2O2S: C, 61.61; H, 3.27; N, 7.56. Found: C, 61.47; H, 3.54; N, 7.41.

2-(5-(4-Fluorophenyl)furan-2-yl)-5-(m-tolyl)-1,3,4-thiadiazole (I15)

Yellow solid, m.p. 150–151 °C; IR (KBr) νmax: 1674.65, 1599.38, 1485.52, 1438.45, 1402.97, 1282.53, 1176.32, 1084.21, 1026.43, 1008.25 cm−1. 1H NMR (400 MHz, CDCl3) 2.44 (s, 3H, CH3), 6.76 (d, J = 3.6 Hz, 1H, FuH), 7.13 (t, J = 8.6 Hz, 2H, PhH-Fu), 7.28–7.32 (m, 2H, FuH + PhH-Thia), 7.38 (t, J = 7.4 Hz, 1H, PhH-Thia), 7.72–7.84 (m, 4H, 2PhH-Thia + 2PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 167.23 (C-2, Thia), 162.77 (d, 1JC-F = 247.6 Hz, C-4, Ph-Fu), 157.86 (C-5, Thia), 155.41 (C-5, Fu), 144.89 (C-2, Fu), 139.04 (C-3′, Ph-Thia), 131.92 (C-2′, Ph-Thia), 129.72 (C-1′, Ph-Thia), 129.06 (C-5′, Ph-Thia), 128.33 (C-4′, Ph-Thia), 126.12 (2C, d, 3JC-F = 8.2 Hz, C-2, C-6, Ph-Fu), 125.87 (d, 4JC-F = 3.3 Hz, C-1, Ph-Fu), 125.07 (C-6′, Ph-Thia), 115.97 (2C, d, 2JC-F = 21.3 Hz, C-3, C-5, Ph-Fu), 113.73 (C-3, Fu), 107.41 (C-4, Fu), 21.31 (CH3). ESIMS (m/z): 337.1 [M + H]+. Anal. Calcd. (%) for C19H13FN2OS: C, 67.84; H, 3.90; N, 8.33. Found: C, 68.09; H, 4.17; N, 8.14.

2-(2-Chlorophenyl)-5-(5-(3-fluorophenyl)furan-2-yl)-1,3,4-thiadiazole (I16)

Light yellow solid, m.p. 154–155 °C; IR (KBr) νmax: 1689.53, 1617.42, 1592.42, 1503.87, 1489.23, 1464.22, 1421.73, 1227.52, 1155.15, 1085.83, 1019.74 cm−1. 1H NMR (400 MHz, CDCl3) 6.88 (d, J = 3.6 Hz, 1H, FuH), 7.05 (td, J = 2.0, 8.0 Hz, 1H, PhH-Fu), 7.35 (d, J = 3.2 Hz, 1H, FuH), 7.39–7.50 (m, 4H, 2PhH-Thia + 2PhH-Fu), 7.55–7.58 (m, 2H, PhH-Thia + PhH-Fu), 8.40–8.43 (m, 1H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 163.15 (d, 1JC-F = 244.6 Hz, C-3, Ph-Fu), 162.51(C-2, Thia), 159.49 (C-5, Thia), 155.21 (d, 4JC-F = 3.1 Hz, C-5, Fu), 145.30 (C-2, Fu), 132.50 (C-1′, Ph-Thia), 131.68 (C-4′, Ph-Thia), 131.50 (d, 3JC-F = 8.5 Hz, C-1, Ph-Fu), 131.16 (C-3′, Ph-Thia), 130.64 (C-6′, Ph-Thia), 130.59 (d, 3JC-F = 9.8 Hz, C-5, Ph-Fu), 128.77 (C-2′, Ph-Thia), 127.44 (C-5′, Ph-Thia), 120.06 (d, 4JC-F = 2.9 Hz, C-6, Ph-Fu), 115.46 (d, 2JC-F = 21.3 Hz, C-2, Ph-Fu), 113.89 (C-3, Fu), 111.26 (d, 2JC-F = 23.6 Hz, C-4, Ph-Fu), 108.74 (C-4, Fu). ESIMS (m/z): 357.1 [M + H]+. Anal. Calcd. (%) for C18H10ClFN2OS: C, 60.59; H, 2.82; N, 7.85. Found: C, 60.34; H, 3.01; N, 7.64.

2-(5-(4-Fluorophenyl)furan-2-yl)-5-(p-tolyl)-1,3,4-thiadiazole (I17)

Yellow solid, m.p. 190–191 °C; IR (KBr) νmax: 1666.35, 1599.26, 1527.48, 1495.29, 1452.27, 1426.73, 1281.37, 1182.92, 1094.11, 1016.43 cm−1. 1H NMR (400 MHz, CDCl3) 2.43 (s, 3H, CH3), 6.77 (d, J = 3.6 Hz, 1H, FuH), 7.14 (t, J = 8.6 Hz, 2H, PhH-Fu), 7.28 (d, J = 3.6 Hz, 1H, FuH), 7.30 (d, J = 8.0 Hz, 2H, PhH-Thia), 7.73–7.77 (m, 2H, PhH-Fu), 7.90 (d, J = 8.0 Hz, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 167.25 (C-2, Thia), 162.83 (d, 1JC-F = 247.7 Hz, C-4, Ph-Fu), 157.71 (C-5, Thia), 155.46 (C-5, Fu), 145.02 (C-2, Fu), 141.69 (C-4′, Ph-Thia), 129.92 (2C, C-3′, C-5′, Ph-Thia), 127.83 (2C, C-2′, C-6′, Ph-Thia), 127.20 (C-1′, Ph-Thia), 126.23 (2C, d, 3JC-F = 8.2 Hz, C-2, C-6, Ph-Fu), 125.97 (d, 4JC-F = 3.3 Hz, C-1, Ph-Fu), 116.04 (2C, d, 2JC-F = 21.9 Hz, C-3, C-5, Ph-Fu), 113.70 (C-3, Fu), 107.45 (C-4, Fu), 21.54 (CH3). ESIMS (m/z): 337.2 [M + H]+. Anal. Calcd. (%) for C19H13FN2OS: C, 67.84; H, 3.90; N, 8.33. Found: C, 67.59; H, 3.67; N, 8.62.

2-(5-(4-Fluorophenyl)furan-2-yl)-5-phenyl-1,3,4-thiadiazole (I18)

Yellow solid, m.p. 178–179 °C; IR (KBr) νmax: 1683.25, 1616.32, 1583.46, 1497.63, 1454.12, 1437.65, 1284.92, 1239.63, 1192.42, 1081.23, 1014.21 cm−1. 1H NMR (400 MHz, CDCl3) 6.77 (d, J = 3.6 Hz, 1H, FuH), 7.14 (t, J = 8.6 Hz, 2H, PhH-Fu), 7.30 (d, J = 4.0 Hz, 1H, FuH), 7.50–7.52 (m, 3H, PhH-Thia), 7.73–7.77 (m, 2H, PhH-Fu), 8.00–8.03 (m, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 167.08 (C-2, Thia), 162.85 (d, 1JC-F = 247.7 Hz, C-4, Ph-Fu), 158.06 (C-5, Thia), 155.57 (C-5, Fu), 144.95 (C-2, Fu), 131.15 (C-1′, Ph-Thia), 129.93 (C-4′, Ph-Thia), 129.23 (2C, C-2′, C-6′, Ph-Thia), 127.91 (2C, C-3′, C-5′, Ph-Thia), 126.25 (2C, d, 3JC-F = 8.2 Hz, C-2, C-6, Ph-Fu), 125.94 (d, 4JC-F = 3.4 Hz, C-1, Ph-Fu), 116.05 (2C, d, 2JC-F = 22.0 Hz, C-3, C-5, Ph-Fu), 113.84 (C-3, Fu), 107.46 (C-4, Fu). ESIMS (m/z): 323.1 [M + H]+. Anal. Calcd. (%) for C18H11FN2OS: C, 67.07; H, 3.44; N, 8.69. Found: C, 67.28; H, 3.21; N, 8.86.

2-(4-Chlorophenyl)-5-(5-phenylfuran-2-yl)-1,3,4-thiadiazole (I19)

Yellow solid, m.p. 185–186 °C; IR (KBr) νmax: 1612.52, 1573.42, 1447.33, 1434.32, 1417.25, 1244.22, 1219.33, 1061.43, 1021.52 cm−1. 1H NMR (400 MHz, CDCl3) 6.84 (d, J = 3.6 Hz, 1H, FuH), 7.32 (d, J = 3.6 Hz, 1H, FuH), 7.33–7.37 (m, 1H, PhH-Fu), 7.42–7.48 (m, 4H, 2PhH-Thia + 2PhH-Fu), 7.76–7.78 (m, 2H, PhH-Fu), 7.94 (d, J = 8.4 Hz, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 165.71 (C-2, Thia), 158.33 (C-5, Thia), 156.58 (C-5, Fu), 144.74 (C-2, Fu), 137.15 (C-4′, Ph-Thia), 129.47 (2C, C-3′, C-5′, Ph-Thia), 129.44 (C-1, Ph-Fu), 128.98 (2C, C-2′, C-6′, Ph-Thia), 128.90 (2C, C-3, C-5, Ph-Fu), 128.68 (C-4, Ph-Fu), 128.45 (C-1′, Ph-Thia), 124.33 (2C, C-2, C-6, Ph-Fu), 113.96 (C-3, Fu), 107.81 (C-4, Fu). ESIMS (m/z): 339.1 [M + H]+. Anal. Calcd. (%) for C18H11ClN2OS: C, 63.81; H, 3.27; N, 8.27. Found: C, 64.12; H, 3.49; N, 7.98.

2-(2-Chlorophenyl)-5-(5-phenylfuran-2-yl)-1,3,4-thiadiazole (I20)

Yellow solid, m.p. 133–134 °C; IR (KBr) νmax: 1612.52, 1573.42, 1532.38, 1439.83, 1424.12, 1410.16, 1224.22, 1209.43, 1031.23, 1012.57 cm−1. 1H NMR (400 MHz, CDCl3) 6.86 (d, J = 3.2 Hz, 1H, FuH), 7.34–7.38 (m, 2H, FuH + PhH-Fu), 7.44–7.47 (m, 4H, 2PhH-Thia + 2PhH-Fu), 7.54–7.58 (m, 1H, PhH-Thia), 7.79–7.81 (m, 2H, PhH-Fu), 8.40–8.42 (m, 1H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 162.24 (C-2, Thia), 159.72 (C-5, Thia), 156.58 (C-5, Fu), 144.85 (C-2, Fu), 132.44 (C-1′, Ph-Thia), 131.56 (C-4′, Ph-Thia), 131.13 (C-3′, Ph-Thia), 130.60 (C-6′, Ph-Thia), 129.50 (C-1, Ph-Fu), 128.88 (2C, C-3, C-5, Ph-Fu), 128.85 (C-2′, Ph-Thia), 128.62 (C-4, Ph-Fu), 127.40 (C-5′, Ph-Thia), 124.37 (2C, C-2, C-6, Ph-Fu), 113.94 (C-3, Fu), 107.77 (C-4, Fu). ESIMS (m/z): 339.2 [M + H]+. Anal. Calcd. (%) for C18H11ClN2OS: C, 63.81; H, 3.27; N, 8.27. Found: C, 63.64; H, 3.51; N, 8.36.

2-(5-(4-Methoxyphenyl)furan-2-yl)-5-(m-tolyl)-1,3,4-thiadiazole (I21)

Yellow solid, m.p. 123–124 °C; IR (KBr) νmax: 1602.63, 1556.22, 1507.38, 1468.37, 1422.45, 1297.62, 1219.65, 1154.79, 1073.64, 1011.16 cm−1. 1H NMR (400 MHz, CDCl3) 2.45 (s, 3H, CH3), 3.86 (s, 3H, OCH3), 6.70 (d, J = 3.6 Hz, 1H, FuH), 6.96 (d, J = 8.8 Hz, 2H, PhH-Fu), 7.27–7.32 (m, 2H, FuH + PhH-Thia), 7.36–7.40 (m, 1H, PhH-Thia), 7.70 (d, J = 8.8 Hz, 2H, PhH-Fu), 7.78 (d, J = 7.6 Hz, 1H, PhH-Thia), 7.84 (s, 1H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 166.96 (C-2, Thia), 159.97 (C-5, Thia), 158.18 (C-4, Ph-Fu), 156.58 (C-5, Fu), 144.30 (C-2, Fu), 139.04 (C-3′, Ph-Thia), 131.83 (C-2′, Ph-Thia), 129.88 (C-1′, Ph-Thia), 129.06 (C-5′, Ph-Thia), 128.36 (C-4′, Ph-Thia), 125.88 (C-6′, Ph-Thia), 125.09 (2C, C-2, C-6, Ph-Fu), 122.52 (C-1, Ph-Fu), 114.32 (2C, C-3, C-5, Ph-Fu), 113.87 (C-3, Fu), 106.24 (C-4, Fu), 55.37 (OCH3), 21.35 (CH3). ESIMS (m/z): 371.2[M + Na]+. Anal. Calcd. (%) for C20H16N2O2S: C, 68.94; H, 4.63; N, 8.04. Found: C, 69.18; H, 4.47; N, 8.33.

2-(4-Chlorophenyl)-5-(5-(p-tolyl)furan-2-yl)-1,3,4-thiadiazole (I22)

Brown solid, m.p. 211–212 °C; IR (KBr) νmax: 1639.26, 1576.02, 1498.87, 1462.85, 1425.37, 1288.42, 1250.65, 1134.79, 1040.05, 1013.13 cm−1. 1H NMR (400 MHz, CDCl3) 6.78 (d, J = 3.2 Hz, 1H, FuH), 7.25 (d, J = 8.4 Hz, 2H, PhH-Fu), 7.31 (d, J = 3.2 Hz, 1H, FuH), 7.47 (d, J = 8.8 Hz, 2H, PhH-Thia), 7.66 (d, J = 8.0 Hz, 2H, PhH-Fu), 7.95 (d, J = 8.8 Hz, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 165.57 (C-2, Thia), 158.44 (C-5, Thia), 156.91 (C-5, Fu), 144.36 (C-2, Fu), 138.82 (C-4, Ph-Fu), 137.11 (C-4′, Ph-Thia), 129.59 (2C, C-3, C-5, Ph-Fu), 129.46 (2C, C-3′, C-5′, Ph-Thia), 128.98 (2C, C-2′, C-6′, Ph-Thia), 128.49 (C-1′, Ph-Thia), 126.77 (C-1, Ph-Fu), 124.32 (2C, C-2, C-6, Ph-Fu), 114.05 (C-3, Fu), 107.15 (C-4, Fu), 21.41 (CH3). ESIMS (m/z): 353.1 [M + H]+. Anal. Calcd. (%) for C19H13ClN2OS: C, 64.68; H, 3.71; N, 7.94. Found: C, 64.49; H, 3.92; N, 7.76.

2-(5-(2-Fluorophenyl)furan-2-yl)-5-(4-methoxyphenyl)-1,3,4-thiadiazole (I23)

Yellow solid, m.p. 171–172 °C; IR (KBr) νmax: 1719.16, 1673.19, 1566.92, 1503.58, 1468.47, 1418.69, 1273.12, 1240.45, 1124.69, 1020.06, 1011.43 cm−1. 1H NMR (400 MHz, CDCl3) 7.00–7.03 (m, 3H, FuH + 2PhH-Thia), 7.14–7.19 (m, 1H, PhH-Fu), 7.24–7.28 (m, 1H, PhH-Fu), 7.29–7.35 (m, 2H, FuH + PhH-Fu), 7.92–7.97 (m, 3H, 2PhH-Thia + PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 167.06 (C-2, Thia), 161.97 (C-4′, Ph-Thia), 159.02 (d, 1JC-F = 250.4 Hz, C-2, Ph-Fu), 157.27 (C-5, Thia), 150.37 (d, 4JC-F = 3.1 Hz, C-5, Fu), 144.84 (C-2, Fu), 129.57 (d, 3JC-F = 8.5 Hz, C-4, Ph-Fu), 129.48 (2C, C-2′, C-6′, Ph-Thia), 126.32 (d, 4JC-F = 2.6 Hz, C-4, Fu), 124.51 (d, 4JC-F = 3.5 Hz, C-5, Ph-Fu), 122.58 (C-1′, Ph-Thia), 117.98 (d, 2JC-F = 11.8 Hz, C-1, Ph-Fu), 116.14 (d, 2JC-F = 21.3 Hz, C-3, Ph-Fu), 114.59 (2C, C-3′, C-5′, Ph-Thia), 113.65 (C-3, Fu), 112.65 (d, 3JC-F = 12.2 Hz, C-6, Ph-Fu), 55.49 (OCH3). ESIMS (m/z): 375.2 [M + Na]+. Anal. Calcd. (%) for C19H13FN2O2S: C, 64.76; H, 3.72; N, 7.95. Found: C, 64.76; H, 3.72; N, 7.95.

2-(5-(2-Fluorophenyl)furan-2-yl)-5-(m-tolyl)-1,3,4-thiadiazole (I24)

Yellow solid, m.p. 130–131 °C; IR (KBr) νmax: 1699.27, 1664.38, 1576.32, 1498.87, 1472.15, 1421.97, 1283.72, 1254.35, 1184.29, 1109.27, 1025.16 cm−1. 1H NMR (400 MHz, CDCl3) 7.03 (t, J = 3.6 Hz, 1H, FuH), 7.14–7.19 (m, 1H, PhH-Fu), 7.23–7.32 (m, 4H, FuH + PhH-Thia + 2PhH-Fu), 7.36–7.40 (m, 1H, PhH-Thia), 7.79 (d, J = 7.6 Hz, 1H, PhH-Thia), 7.85 (s, 1H, PhH-Thia), 7.92–7.96 (m, 1H, PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 167.43 (C-2, Thia), 159.01 (d, 1JC-F = 250.5 Hz, C-2, Ph-Fu), 157.85 (C-5, Thia), 150.49 (d, 4JC-F = 3.1 Hz, C-5, Fu), 144.76 (C-2, Fu), 139.07 (C-3′, Ph-Thia), 131.96 (C-2′, Ph-Thia), 129.75 (C-1′, Ph-Thia), 129.61 (d, 3JC-F = 8.4 Hz, C-4, Ph-Fu), 129.08 (C-5′, Ph-Thia), 128.39 (C-4′, Ph-Thia), 126.30 (d, 4JC-F = 2.6 Hz, C-4, Fu), 125.13 (C-6′, Ph-Thia), 124.50 (d, 4JC-F = 3.5 Hz, C-5, Ph-Fu), 117.90 (d, 2JC-F = 11.8 Hz, C-1, Ph-Fu), 116.18 (d, 2JC-F = 21.2 Hz, C-3, Ph-Fu), 113.84 (C-3, Fu), 112.65 (d, 3JC-F = 12.2 Hz, C-6, Ph-Fu), 21.33 (CH3). ESIMS (m/z): 337.2 [M + H]+. Anal. Calcd. (%) for C19H13FN2OS: C, 67.84; H, 3.90; N, 8.33. Found: C, 67.59; H, 4.13; N, 8.17.

2-(5-(2-Fluorophenyl)furan-2-yl)-5-phenyl-1,3,4-thiadiazole (I25)

Yellow solid, m.p. 112–113 °C; IR (KBr) νmax: 1689.46, 1598.27, 1556.02, 1489.37, 1452.21, 1415.74, 1271.51, 1261.75, 1124.81, 1070.45, 1012.83 cm−1. 1H NMR (400 MHz, CDCl3) 7.03 (t, J = 3.6 Hz, 1H, FuH), 7.15–7.19 (m, 1H, PhH-Fu), 7.24–7.28 (m, 1H, PhH-Fu), 7.30–7.34 (m, 1H, PhH-Fu), 7.35 (d, J = 3.6 Hz, 1H, FuH), 7.49–7.52 (m, 3H, PhH-Thia), 7.95 (td, J = 1.6, 7.6 Hz, 1H, PhH-Fu), 8.01–8.03 (m, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 167.22 (C-2, Thia), 159.05 (d, 1JC-F = 250.5 Hz, C-2, Ph-Fu), 158.00 (C-5, Thia), 150.58 (d, 4JC-F = 3.1 Hz, C-5, Fu), 144.76 (C-2, Fu), 131.16 (C-1′, Ph-Thia), 129.94 (C-4′, Ph-Thia), 129.66 (d, 3JC-F = 8.4 Hz, C-4, Ph-Fu), 129.23 (2C, C-2′, C-6′, Ph-Thia), 127.93 (2C, C-3′, C-5′, Ph-Thia), 126.34 (d, 4JC-F = 2.6 Hz, C-4, Fu), 124.52 (d, 4JC-F = 3.5 Hz, C-5, Ph-Fu), 117.94 (d, 2JC-F = 11.7 Hz, C-1, Ph-Fu), 116.17 (d, 2JC-F = 21.2 Hz, C-3, Ph-Fu), 113.95 (C-3, Fu), 112.69 (d, 3JC-F = 12.2 Hz, C-6, Ph-Fu). ESIMS (m/z): 323.2 [M + H]+. Anal. Calcd. (%) for C18H11FN2OS: C, 67.07; H, 3.44; N, 8.69. Found: C, 66.81; H, 3.74; N, 8.95.

2-(5-(4-Chlorophenyl)furan-2-yl)-5-(p-tolyl)-1,3,4-thiadiazole (I26)

Yellow solid, m.p. 185–186 °C; IR (KBr) νmax: 2916.81, 1588.09, 1478.17, 1442.49, 1279.54, 1182.15, 1107.90, 1091.51, 1047.16 cm−1. 1H NMR (400 MHz, CDCl3) 2.43 (s, 3H, CH3), 6.83 (d, J = 3.6 Hz, 1H, FuH), 7.29 (d, J = 4.0 Hz, 1H, FuH), 7.31 (d, J = 8.4 Hz, 2H, PhH-Thia), 7.41 (d, J = 8.4 Hz, 2H, PhH-Fu), 7.70 (d, J = 8.8 Hz, 2H, PhH-Fu), 7.90 (d, J = 8.0 Hz, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 167.36 (C-2, Thia), 157.60 (C-5, Thia), 155.19 (C-5, Fu), 145.19 (C-2, Fu), 141.73 (C-4′, Ph-Thia), 134.34 (C-4, Ph-Fu), 129.91 (2C, C-3′, C-5′, Ph-Thia), 129.13 (2C, C-3, C-5, Ph-Fu), 128.02 (C-1, Ph-Fu), 127.82 (2C, C-2′, C-6′, Ph-Thia), 127.11 (C-1′, Ph-Thia), 125.52 (2C, C-2, C-6, Ph-Fu), 113.70 (C-3, Fu), 108.15 (C-4, Fu), 21.54 (CH3). ESIMS (m/z): 353.2 [M + H]+. Anal. Calcd. (%) for C19H13ClN2OS: C, 64.68; H, 3.71; N, 7.94. Found: C, 64.41; H, 3.98; N, 8.16.

2-(5-(2,6-Difluorophenyl)furan-2-yl)-5-(4-methoxyphenyl)-1,3,4-thiadiazole (I27)

Yellow solid, m.p. 178–179 °C; IR (KBr) νmax: 3297.46, 2936.51, 1628.17, 1596.25, 1562.36, 1488.27, 1452.34, 1279.34, 1162.95, 1106.70, 1071.51, 1037.16, 1012.37 cm−1. 1H NMR (400 MHz, CDCl3) 3.89 (s, 3H, OCH3), 6.99–7.05 (m, 5H, FuH + 2PhH-Thia + 2PhH-Fu), 7.28–7.32 (m, 1H, PhH-Fu), 7.36 (d, J = 3.2 Hz, 1H, FuH), 7.96 (d, J = 8.8 Hz, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 167.31 (C-2, Thia), 161.96 (C-4′, Ph-Thia), 159.46 (2C, dd, 1JC-F = 253.2 Hz, 3JC-F = 6.6 Hz, C-2, C-6, Ph-Fu), 157.37 (C-5, Thia), 146.13 (dd, 4JC-F = 2.2 Hz, 4JC-F = 2.3 Hz, C-5, Fu), 145.81 (dd, 5JC-F = 1.7 Hz, 5JC-F = 1.7 Hz, C-2, Fu), 129.50 (2C, C-2′, C-6′, Ph-Thia), 129.48 (dd, 3JC-F = 10.6 Hz, 3JC-F = 10.5 Hz, C-4, Ph-Fu), 122.65 (C-1′, Ph-Thia), 114.88 (dd, 3JC-F = 6.4 Hz, 3JC-F = 6.4 Hz, C-4, Fu), 114.58 (2C, C-3′, C-5′, Ph-Thia), 112.31 (C-3, Fu), 112.18 (2C, dd, 2JC-F = 19.8 Hz, 4JC-F = 5.7 Hz, C-3, C-5, Ph-Fu), 108.27 (dd, 2JC-F = 15.5 Hz, 2JC-F = 15.6 Hz, C-1, Ph-Fu), 55.50 (OCH3). ESIMS (m/z): 393.2 [M + Na]+. Anal. Calcd. (%) for C19H12F2N2O2S: C, 61.61; H, 3.27; N, 7.56. Found: C, 61.38; H, 3.54; N, 7.23.

2-(4-Chlorophenyl)-5-(5-(2,6-difluorophenyl)furan-2-yl)-1,3,4-thiadiazole (I28)

Yellow solid, m.p. 204–205 °C; IR (KBr) νmax: 3167.46, 2962.43, 1683.77, 1607.38, 1576.65, 1532.27, 1489.57, 1432.14, 1281.34, 1182.55, 1136.51, 1037.16 cm−1. 1H NMR (400 MHz, CDCl3) 7.01–7.06 (m, 3H, FuH + 2PhH-Fu), 7.29–7.33 (m, 1H, PhH-Fu), 7.40 (d, J = 3.2 Hz, 1H, FuH), 7.48 (dd, J = 2.0, 6.8 Hz, 2H, PhH-Thia), 7.96 (dd, J = 2.0, 6.8 Hz, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 166.21 (C-2, Thia), 158.28 (C-5, Thia), 159.45 (2C, dd, 1JC-F = 253.3 Hz, 3JC-F = 6.5 Hz, C-2, C-6, Ph-Fu), 146.52 (dd, 4JC-F = 2.3 Hz, 4JC-F = 2.3 Hz, C-5, Fu), 145.47 (dd, 5JC-F = 1.8 Hz, 5JC-F = 1.8 Hz, C-2, Fu), 137.23 (C-4′, Ph-Thia), 129.65 (dd, 3JC-F = 10.6 Hz, 3JC-F = 10.6 Hz, C-4, Ph-Fu), 129.49 (2C, C-3′, C-5′, Ph-Thia), 129.05 (2C, C-2′, C-6′, Ph-Thia), 128.43 (C-1′, Ph-Thia), 114.93 (dd, 3JC-F = 6.5 Hz, 3JC-F = 6.4 Hz, C-4, Fu), 112.31 (C-3, Fu), 112.20 (2C, dd, 2JC-F = 19.9 Hz, 4JC-F = 5.7 Hz, C-3, C-5, Ph-Fu), 108.14 (dd, 2JC-F = 15.5 Hz, 2JC-F = 15.4 Hz, C-1, Ph-Fu). ESIMS (m/z): 375.1 [M + H]+. Anal. Calcd. (%) for C18H9ClF2N2OS: C, 57.68; H, 2.42; N, 7.47. Found: C, 57.92; H, 2.21; N, 7.69.

2-(2-Chlorophenyl)-5-(5-(2-nitrophenyl)furan-2-yl)-1,3,4-thiadiazole (I29)

Brown solid, m.p. 148–149 °C; IR (KBr) νmax: 2928.35, 1617.63, 1528.54, 1482.13, 1451.37, 1427.33, 1338.32, 1319.32, 1268.91, 1185.43, 1109.62, 1022.24, 1018.51 cm−1. 1H NMR (400 MHz, CDCl3) 6.87 (d, J = 4.0 Hz, 1H, FuH), 7.36 (d, J = 4.0 Hz, 1H, FuH), 7.44–7.46 (m, 2H, PhH-Thia), 7.50–7.57 (m, 2H, PhH-Thia + PhH-Fu), 7.65–7.69 (m, 1H, PhH-Fu), 7.79 (dd, J = 0.8, 8.0 Hz, 1H, PhH-Fu), 7.84 (dd, J = 1.0, 8.0 Hz, 1H, PhH-Fu), 8.37–8.39 (m, 1H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 162.93 (C-2, Thia), 159.14 (C-5, Thia), 150.67 (C-5, Fu), 147.64 (C-2, Ph-Fu), 146.40 (C-2, Fu), 132.55 (C-1′, Ph-Thia), 132.22 (C-4, Ph-Fu), 131.72 (C-4′, Ph-Thia), 131.18 (C-3′, Ph-Thia), 130.61 (C-6′, Ph-Thia), 129.41 (C-5, Ph-Fu), 129.30 (C-3, Ph-Fu), 128.66 (C-2′, Ph-Thia), 127.40 (C-5′, Ph-Thia), 124.19 (C-6, Ph-Fu), 123.04 (C-1, Ph-Fu), 113.44 (C-3, Fu), 112.35 (C-4, Fu). ESIMS (m/z): 384.1 [M + H]+. Anal. Calcd. (%) for C18H10ClN3O3S: C, 56.33; H, 2.63; N, 10.95. Found: C, 56.08; H, 2.39; N, 11.14.

2-(5-(2-Nitrophenyl)furan-2-yl)-5-(p-tolyl)-1,3,4-thiadiazole (I30)

Yellow solid, m.p. 146–147 °C; IR (KBr) νmax: 1642.52, 1521.51, 1474.31, 1446.39, 1417.45, 1339.23, 1301.39, 1278.32, 1164.34, 1117.36, 1021.59 cm−1. 1H NMR (400 MHz, CDCl3) 2.43 (s, 3H, CH3), 6.87 (d, J = 4.0 Hz, 1H, FuH), 7.30 (d, J = 8.4 Hz, 2H, PhH-Thia), 7.32 (d, J = 4.0 Hz, 1H, FuH), 7.49–7.53 (m, 1H, PhH-Fu), 7.64–7.67 (m, 1H, PhH-Fu), 7.77–7.82 (m, 2H, PhH-Fu), 7.90 (d, J = 8.0 Hz, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 167.91 (C-2, Thia), 157.24 (C-5, Thia), 150.51 (C-5, Fu), 147.62 (C-2, Ph-Fu), 146.66 (C-2, Fu), 141.80 (C-4′, Ph-Thia), 132.14 (C-4, Ph-Fu), 129.90 (2C, C-3′, C-5′, Ph-Thia), 129.34 (C-5, Ph-Fu), 129.14 (C-3, Ph-Fu), 127.91 (2C, C-2′, C-6′, Ph-Thia), 127.06 (C-1′, Ph-Thia), 124.18 (C-6, Ph-Fu), 122.99 (C-1, Ph-Fu), 112.95 (C-3, Fu), 112.24 (C-4, Fu), 21.55 (CH3). ESIMS (m/z): 364.1 [M + H]+. Anal. Calcd. (%) for C19H13N3O3S: C, 62.80; H, 3.61; N, 11.56. Found: C, 63.02; H, 3.83; N, 11.39.

2-(4-Methoxyphenyl)-5-(5-(3-nitrophenyl)furan-2-yl)-1,3,4-thiadiazole (I31)

Yellow solid, m.p. 200–201 °C; IR (KBr) νmax: 3096.43, 1617.56, 1516.83, 1497.91, 1458.23, 1341.53, 1310.35, 1276.39, 1163.47, 11091.6, 1031.42 cm−1. 1H NMR (400 MHz, CDCl3) 3.90 (s, 3H, OCH3), 7.00–7.03 (m, 3H, FuH + 2PhH-Thia), 7.33 (d, J = 3.6 Hz, 1H, FuH), 7.61–7.65 (m, 1H, PhH-Fu), 7.97 (d, J = 8.8 Hz, 2H, PhH-Thia), 8.06–8.09 (m, 1H, PhH-Fu), 8.17–8.20 (m, 1H, PhH-Fu), 8.50–8.58 (m, 1H, PhH-Fu). 13C NMR (100 MHz, CDCl3) δ 167.44 (C-2, Thia), 162.09 (C-4′, Ph-Thia), 156.80 (C-5, Thia), 153.40 (C-5, Fu), 148.78 (C-3, Ph-Fu), 146.27 (C-2, Fu), 131.12 (C-1, Ph-Fu), 130.02 (C-6, Ph-Fu), 129.68 (C-5, Ph-Fu), 129.54 (2C, C-2′, C-6′, Ph-Thia), 122.76 (C-4, Ph-Fu), 122.42 (C-1′, Ph-Thia), 118.94 (C-2, Ph-Fu), 114.64 (2C, C-3′, C-5′, Ph-Thia), 113.40 (C-3, Fu), 109.85 (C-4, Fu), 55.52 (OCH3). ESIMS (m/z): 380.2 [M + H]+. Anal. Calcd. (%) for C19H13N3O4S: C, 60.15; H, 3.45; N, 11.08. Found: C, 59.89; H, 3.68; N, 11.21.

2-(5-(2,6-Difluorophenyl)furan-2-yl)-5-phenyl-1,3,4-thiadiazole (I32)

Yellow solid, m.p. 196–197 °C; IR (KBr) νmax: 3147.76, 2982.53, 1673.37, 1601.28, 1566.45, 1522.16, 1484.25, 1421.78, 1280.54, 1182.43, 1135.69 cm−1. 1H NMR (400 MHz, CDCl3) 7.00–7.05 (m, 3H, FuH + 2PhH-Fu), 7.28–7.32 (m, 1H, PhH-Fu), 7.39 (d, J = 3.6 Hz, 1H, FuH), 7.49–7.52 (m, 3H, PhH-Thia), 8.00–8.03 (m, 2H, PhH-Thia). 13C NMR (100 MHz, CDCl3) δ 167.50 (C-2, Thia), 159.46 (2C, dd, 1JC-F = 253.2 Hz, 3JC-F = 6.5 Hz, C-2, C-6, Ph-Fu), 158.10 (C-5, Thia), 146.35 (dd, 4JC-F = 2.3 Hz, 4JC-F = 2.3 Hz, C-5, Fu), 145.68 (dd, 5JC-F = 1.7 Hz, 5JC-F = 1.7 Hz, C-2, Fu), 131.15 (C-1′, Ph-Thia), 129.95 (C-4′, Ph-Thia), 129.57 (dd, 3JC-F = 10.6 Hz, 3JC-F = 10.5 Hz, C-4, Ph-Fu), 129.21 (2C, C-2′, C-6′, Ph-Thia), 127.93 (2C, C-3′, C-5′, Ph-Thia), 114.91 (dd, 3JC-F = 6.4 Hz, 3JC-F = 6.4 Hz, C-4, Fu), 112.30 (C-3, Fu), 112.20 (2C, dd, 2JC-F = 19.9 Hz, 4JC-F = 5.7 Hz, C-3, C-5, Ph-Fu), 108.21 (dd, 2JC-F = 15.5 Hz, 2JC-F = 15.5 Hz, C-1, Ph-Fu). ESIMS (m/z): 341.2 [M + H]+. Anal. Calcd. (%) for C18H10F2N2OS: C, 63.52; H, 2.96; N, 8.23. Found: C, 63.37; H, 2.75; N, 8.46.

Bioassays

In vitro fungicidal activity

In vitro fungicidal activity of the title compounds against Phytophthora infestans, Valsa mali, Phomopsis aspamgi, Cladosporium fulvum Cke., Alternaria tenuis Nees and other twenty panthogenic fungi listed in Table 4 were evaluated using mycelium growth rate test22,30. The tested compounds were dissolved in DMSO (dimethyl sulfoxide) and mixed with sterile molten potato dextrose agar to a final concentration of 50 μg mL−1. Commercial fungicides pyrimorph and hymexazol were used as controls against the above mentioned fungal pathogens under the same conditions. Three replicates were performed. The relative inhibitory rate of title compounds compared to blank control was calculated via the following equation (1):

In which, I stands for the rate of inhibition (%), C is the diameter of mycelia in the blank control test (in mm) and T is the diameter of mycelia in the presence of tested compounds (in mm). The EC50 values of title compounds were evaluated using logit analysis (Table 2). EC50 results were analyzed using the statistical data processing system (DPS, 10.15, Zhejiang, China).

In vivo antifungal activity

Using the pot culture test22,28, in vivo antifungal activities of the title compounds against P. infestans, V. mali, P. aspamgi and C. fulvum Cke. were evaluated in greenhouse along with commercial fungicides pyrimorph and hymexazol as controls.

The culture plates were cultivated at 24 ± 1 °C. Soaking cucumber seeds in water for 2 h at 50 oC and then, keeping the seeds moist for 24 h at 28 oC in an incubator. When the radicles were 0.5 cm, the seeds were grown in plastic pots containing a 1:1 (v/v) mixture of vermiculite and peat. Cucumber plants used for inoculations were at the stage of two seed leaves.

Tested compounds were confected to 2.5% EC (emulsifiable cocentration) formulations, in which pesticide emulsifier 600 (2.125%) and pesticide emulsifier 500 (0.375%) were the additives, DMSO (0.1%) was the solvent and xylene was the co-solvent. The formulation was diluted to 500 μg mL−1 with water. The pathogenic fungi were inoculated on the surface of seed leaves and then the solution of title compounds was sprayed with a hand sprayer, respectively. Three replicates for each treatment were applied. After inoculation, the plants were maintained at 24 ± 1 oC and above 80% relative humidity.

When the untreated cucumber plant (blank control) fully developed symptoms, the fungicidal activity was assessed. The area of inoculated leaves covered by disease symptoms was evaluated and compared to that of untreated ones to determine the average disease index. The relative control efficacy of compounds compared to the blank assay was calculated via the following equation (2):

where I is relative control efficacy, CK is the average disease index during the blank assay and PT is the average disease index after treatment during testing. The results are shown in Table 3.

Electron microscopy42,43

Scanning electron microscopy (SEM)

Mycelial tip (5 mm) of P. capsici from an actively growing colony on PDA medium, which were treated by I18 at 50 μg mL−1, were cut from the edge of the colony after cultured for 72 h. The tips were treated with 4% glutaraldehyde at 4 oC and then, rinsed with 0.1 M phosphate buffer (pH 7.3) and fixed with 1% w/v osmium tetraoxide solution. The mycelial tips were dehydrated using a series of acetone solutions in the order of concentration 30, 50, 70, 80 and 90% anhydrous acetone, after rinsed with 0.1 M phosphate buffer three times. After completing the processes of drying at critical point, mounting and gold spraying, the mycelial tip was examined by a scanning electron microscope (S-3400N, Hitachi, Nissei Sanyo, Japan) with an accelerating voltage of 18–20 kV.

Transmission electron microscopy (TEM)

The mycelial tip was prepared according to the same method mentioned above. After dehydrating and embedding in Epon 112, thin sections were cut and double-stained with uranyl acetate and lead citrate. The grids were examined with a JEOL-1230 (JEOL, Tokyo, Japan) transmission electron microscope.

Additional Information

How to cite this article: Cui, Z.-N. et al. Synthesis and fungicidal activity of novel 2,5-disubstituted-1,3,4- thiadiazole derivatives containing 5-phenyl-2-furan. Sci. Rep. 6, 20204; doi: 10.1038/srep20204 (2016).